Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia

Published:2017-05-08 Issue:1 Volume:7 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Duggan Brittany M.,Foley Kevin P.,Henriksbo Brandyn D.,Cavallari Joseph F.,Tamrakar Akhilesh K.,Schertzer Jonathan D.

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-017-01822-0.pdf

Reference60 articles.

1. Wu, P., Nielsen, T. E. & Clausen, M. H. FDA-approved small-molecule kinase inhibitors. Trends Pharmacol. Sci. 36, 422–439, doi: 10.1016/j.tips.2015.04.005 (2015).

2. Brooks, M. B. Erlotinib appears to produce prolonged remission of insulin-requiring type 2 diabetes associated with metabolic syndrome and chronic kidney disease. Br. J. Diabetes Vasc. Dis 12, 87–90, doi: 10.1177/1474651412442694 (2012).

3. Agostino, N. M. et al. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. J. Oncol. Pharm. Pract. 17, 197–202, doi: 10.1177/1078155210378913 (2011).

4. Breccia, M. et al. Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib. Leuk. Res. 32, 1626–8, doi: 10.1016/j.leukres.2008.01.015 (2008).

5. Breccia, M., Muscaritoli, M., Aversa, Z., Mandelli, F. & Alimena, G. Imatinib mesylate may improve fasting blood glucose in Ph+ Chronic Myelogenous Leukemia patients responsive to treatment. J. Clin. Oncol. 22, 4653–4654, doi: 10.1200/JCO.2004.04.217 (2004).

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bruton’s tyrosine kinase (BTK) inhibitors alter blood glucose and insulin in obese mice but reduce inflammation independent of BTK;American Journal of Physiology-Endocrinology and Metabolism;2024-09-01

2. Receptor Interacting Ser/Thr-Protein Kinase 2 as a New Therapeutic Target;Journal of Medicinal Chemistry;2023-10-19

3. Microbiota and Nod-like receptors balance inflammation and metabolism during obesity and diabetes;Biomedical Journal;2023-10

4. The tyrosine kinase inhibitor Dasatinib reduces cardiac steatosis and fibrosis in obese, type 2 diabetic mice;Cardiovascular Diabetology;2023-08-17

5. The tyrosine kinase inhibitor Dasatinib reduces cardiac steatosis and fibrosis in obese, type 2 diabetic mice;2023-06-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3